Skip to main content
Ronald Buckanovich, MD, Oncology, Ann Arbor, MI

Ronald J Buckanovich MD


Physician

Join to View Full Profile
  • 1500 E Medical Center DrB1 floor Cancer Recp CAnn Arbor, MI 48109

  • Phone+1 734-647-8906

Dr. Buckanovich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1998 - 2001
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1998

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1999 - 2026
  • MI State Medical License
    MI State Medical License 2006 - 2019
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Elected Member The American Society for Clinical Investigation, 2012
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Leukemia Inhibitory Factor Functions in Parallel with Interleukin-6 to Promote Ovarian Cancer Growth  
    Karen McLean, Ronald J Buckanovich, Moshe Talpaz, Nature

Lectures

  • Changing the Perspective for ""Successful"" Maintenance Therapy 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

  • Pitt Study Makes New Insights into the Origins of Ovarian Cancer
    Pitt Study Makes New Insights into the Origins of Ovarian CancerMarch 14th, 2025
  • Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
    Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian CancerOctober 28th, 2019
  • Targeting Stem-like Cells Could Prevent Ovarian Cancer Recurrence
    Targeting Stem-like Cells Could Prevent Ovarian Cancer RecurrenceMarch 12th, 2019
  • Join now to see all

Grant Support

  • Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targetsMAGEE-WOMEN'S RES INST AND FOUNDATION2023–2028
  • Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targetsMAGEE-WOMEN'S RES INST AND FOUNDATION2023–2028
  • HCC Ovarian Cancer SPOREUNIVERSITY OF PITTSBURGH AT PITTSBURGH2023–2028
  • Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targetsMAGEE-WOMEN'S RES INST AND FOUNDATION2023–2028
  • HCC Ovarian Cancer SPOREUNIVERSITY OF PITTSBURGH AT PITTSBURGH2023–2028
  • HCC Ovarian Cancer SPOREUNIVERSITY OF PITTSBURGH AT PITTSBURGH2023–2028
  • Defining the impact of stromal aging on ovarian cancer initiationUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2026
  • ALDH Inhibition as Modulator of Tumor ImmunobiologyMAGEE-WOMEN'S RES INST AND FOUNDATION2020–2025
  • Targeting Ovarian Tumor Associated Myeloid Cells With Nanoparticles TherapeuticsNational Cancer Institute2012
  • Using Embryonic Stem Cells To Re-Create A Human Tumor Microenvironment To DevelopOffice Of The Director, National Institutes Of Health2008

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: